How Many Doses Vial SS-31? (Complete Dosing Breakdown)

Most peptide protocols fail at the mixing stage, not the injection stage. And SS-31 (Elamipretide) is no exception. The question "how many doses vial SS-31" doesn't have a single answer because the dose count depends entirely on three variables: vial size (milligrams of lyophilized peptide), reconstitution volume (milliliters of bacteriostatic water added), and individual dose size (milligrams per injection). A 10mg vial reconstituted with 2mL of bacteriostatic water and dosed at 0.5mg per injection yields 20 doses. The same 10mg vial reconstituted with 5mL and dosed at 1mg yields 10 doses. Understanding this math isn't optional. It determines whether your research compound delivers the intended concentration or becomes ineffective through dilution errors.

We've worked with researchers who've miscalculated their SS-31 dosing by a factor of two simply because they didn't account for reconstitution volume when calculating per-dose milligrams. The gap between doing it right and wasting expensive peptides comes down to understanding the relationship between vial concentration, target dose, and injection volume.

How many doses can you get from an SS-31 vial?

The number of doses from an SS-31 vial depends on total peptide content (typically 5mg, 10mg, or 20mg per vial), reconstitution volume, and target dose per injection. A 10mg vial reconstituted with 2mL bacteriostatic water yields 5mg/mL concentration. At 0.5mg per dose, that's 20 doses; at 1mg per dose, it's 10 doses. Standard research protocols use 0.25mg to 1mg per injection, meaning a single 10mg vial delivers 10–40 doses depending on protocol design.

Here's what SS-31 dosing guides typically skip: reconstitution volume doesn't just affect concentration. It also determines injection volume per dose, which matters for subcutaneous administration comfort and absorption kinetics. A 0.5mg dose from a highly concentrated solution (10mg/1mL) requires only 0.05mL injection volume, while the same 0.5mg dose from a dilute solution (10mg/5mL) requires 0.25mL. Smaller injection volumes reduce tissue irritation but require precise measurement; larger volumes are easier to measure accurately but increase subcutaneous depot size. This article covers how vial size translates to dose count, how reconstitution math works in practice, what dilution mistakes negate peptide stability entirely, and how Real Peptides' research-grade SS-31 maintains consistent amino-acid sequencing across every batch to eliminate concentration variability as a confounding factor.

SS-31 Vial Sizes and Standard Dose Yields

SS-31 is supplied as lyophilized powder in sealed vials containing 5mg, 10mg, or 20mg of peptide. The lyophilized form is stable at room temperature for short periods but should be stored at −20°C before reconstitution to prevent degradation. Once reconstituted with bacteriostatic water, the peptide must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C accelerates oxidative breakdown of the dimethyltyrosine residues that give SS-31 its mitochondrial-targeting properties.

At research-standard concentrations, a 10mg vial reconstituted with 2mL bacteriostatic water yields a 5mg/mL solution. If the protocol calls for 0.5mg per dose, divide total milligrams by dose size: 10mg ÷ 0.5mg = 20 doses. If the protocol uses 0.25mg per dose, the same vial yields 40 doses. The injection volume per dose scales proportionally. 0.5mg from a 5mg/mL solution requires 0.1mL (10 units on an insulin syringe), while 0.25mg requires 0.05mL (5 units). Researchers working with concentrations below 2.5mg/mL often report dosing errors because insulin syringes have minimum measurable increments of 0.01mL (1 unit). Attempting to measure 0.03mL accurately becomes difficult without specialized micro-volume syringes.

Vial size determines total available peptide, but reconstitution volume determines how many milliliters you draw per dose. A 20mg vial reconstituted with 4mL bacteriostatic water yields the same 5mg/mL concentration as a 10mg vial with 2mL. The difference is total volume available. Our experience shows that larger vials reduce per-dose cost but require refrigerator storage discipline: a 20mg vial at 0.5mg per dose lasts 40 injections, which at daily dosing spans six weeks. Most researchers underestimate how quickly peptides degrade once reconstituted if storage temperature fluctuates even briefly above 8°C.

Reconstitution Math: Calculating Concentration and Dose Volume

Reconstitution math follows a simple formula: concentration (mg/mL) = total peptide (mg) ÷ reconstitution volume (mL). A 10mg vial + 2mL bacteriostatic water = 5mg/mL. To calculate injection volume for a target dose, use: injection volume (mL) = target dose (mg) ÷ concentration (mg/mL). For a 0.5mg dose from a 5mg/mL solution: 0.5mg ÷ 5mg/mL = 0.1mL.

The critical mistake most researchers make is choosing reconstitution volume without considering target dose. If your protocol requires 0.25mg per injection and you reconstitute a 10mg vial with 5mL water, you get a 2mg/mL solution. Which means each 0.25mg dose requires 0.125mL injection volume. Insulin syringes measure in 0.01mL increments, so 0.125mL falls between marked lines (between 0.12mL and 0.13mL). That imprecision compounds across multiple doses. Reconstituting the same 10mg vial with 2mL instead yields 5mg/mL, making the 0.25mg dose exactly 0.05mL. Five units on an insulin syringe, a measurable increment with zero rounding error.

Bacteriostatic water (0.9% benzyl alcohol in sterile water) is the required diluent for multi-dose vials. Plain sterile water lacks antimicrobial preservative, meaning bacterial contamination risk increases with every needle puncture after the first. Bacteriostatic water maintains sterility for 28 days under refrigeration. Reconstitution technique matters: inject the water slowly down the vial wall, not directly onto the lyophilized powder, to prevent foaming and peptide denaturation. Gently swirl. Never shake. Until the powder fully dissolves. Any cloudiness or particulate matter after dissolution indicates contamination or degradation; discard the vial immediately.

How Many Doses Vial SS-31: Protocol-Specific Breakdown

This table assumes daily dosing. The total available doses remains fixed by vial size and dose amount. Reconstitution volume affects only concentration and injection volume per dose, not total dose count. A 10mg vial yields exactly 20 doses at 0.5mg regardless of whether you reconstitute with 2mL or 5mL. What changes is whether each dose requires 0.1mL or 0.25mL injection volume.

The 5mg/mL concentration (10mg vial + 2mL water) has become the de facto standard in SS-31 research because it balances measurement precision with injection comfort. Concentrations above 10mg/mL can cause subcutaneous irritation; concentrations below 2mg/mL require larger injection volumes that increase measurement error and tissue depot size. Researchers working with SS-31 for the first time often choose overly dilute solutions (1mg/mL or lower) assuming this reduces side effects. But SS-31 has minimal local tissue reactivity, and the primary driver of discomfort is injection volume, not concentration.

What If: SS-31 Dosing Scenarios

What If I Need to Split a Dose Between Two Injections?

Divide the total dose by two and calculate each injection volume separately. If your protocol requires 1mg total but you prefer two 0.5mg injections (for example, to reduce subcutaneous depot size), a 5mg/mL solution requires 0.1mL per injection. This approach doubles needle punctures but reduces single-site tissue volume, which some researchers find beneficial for subcutaneous administration comfort. The peptide stability and bioavailability remain unchanged. SS-31's half-life of approximately 1–2 hours in circulation means split dosing within the same hour produces equivalent plasma exposure to a single bolus.

What If My Vial Concentration Seems Off After Reconstitution?

Reconstitution errors. Adding 3mL instead of 2mL, or using a 5mg vial when you thought it was 10mg. Are common and unrecoverable. If you suspect incorrect concentration, the only verification method is recalculating from known variables: vial label (milligrams), reconstitution volume added (milliliters), and resulting concentration. There is no at-home assay to confirm peptide concentration post-mixing. If you're uncertain, discard the vial and start over with documented measurements. Underdosing renders the protocol ineffective, and overdosing with mitochondrial-targeting peptides introduces unnecessary risk. Real Peptides labels every vial with batch-specific peptide content verified through HPLC, eliminating vial mislabeling as a variable.

What If I Miss the 28-Day Use Window After Reconstitution?

SS-31 reconstituted with bacteriostatic water degrades measurably after 28 days under refrigeration, with oxidative breakdown of the dimethyltyrosine residues reducing mitochondrial-targeting efficacy. Continuing to use a vial beyond this window doesn't pose acute safety risk. The degradation products are non-toxic. But the peptide potency declines unpredictably, making dose standardization impossible. If you've passed 28 days, discard the vial. To avoid waste, calculate your total protocol duration before reconstitution: if you're dosing 0.5mg daily for 30 days, you need 15mg total peptide, which requires either two 10mg vials (reconstituted sequentially) or one 20mg vial (accepting some waste).

The Clinical Truth About SS-31 Dosing Precision

Here's the honest answer: most SS-31 research fails not because the peptide doesn't work, but because researchers underestimate how much dosing imprecision compounds over multi-week protocols. A 10% measurement error per injection. Drawing 0.11mL instead of 0.1mL. Produces cumulative dose drift of 30% over 30 injections. That's the difference between a subtherapeutic and therapeutic plasma level for mitochondrial peptides with narrow effective concentration ranges.

The published preclinical literature on SS-31 uses dosing precision within ±5%, achieved through calibrated micropipettes and verified reconstitution math. Translating that rigor to independent research settings requires eliminating variables: use pre-calibrated insulin syringes (not reused syringes with worn plungers), verify reconstitution volume with graduated cylinders or precision pipettes rather than estimating syringe markings, and store reconstituted peptides in temperature-monitored refrigerators (not standard household units with variable cooling cycles). The gap between published results and real-world replication often comes down to these overlooked preparation details, not peptide quality.

SS-31's mechanism. Selective accumulation in the inner mitochondrial membrane via electrostatic interaction with cardiolipin. Depends on achieving minimum effective concentrations in circulation. Underdosing by 20–30% due to reconstitution or measurement errors means the peptide never reaches mitochondrial therapeutic threshold. This isn't a peptide failure; it's a protocol execution failure. Our team has reviewed dosing logs from hundreds of researchers in this space, and the pattern is consistent: those who document reconstitution math, verify injection volumes, and adhere to storage protocols report reproducible outcomes; those who estimate measurements report inconsistent results.

SS-31 stability is conditional, not guaranteed. Temperature excursions, improper reconstitution technique, and use beyond the 28-day window all degrade efficacy in ways that visual inspection cannot detect. A clear solution doesn't prove potency. Oxidized peptides remain visually identical to intact peptides. The only safeguard is strict adherence to validated preparation protocols and documented handling procedures from lyophilization to final injection.

The number of doses you extract from an SS-31 vial matters less than whether each dose delivers the intended peptide concentration to the research model. A 10mg vial that yields 18 accurate doses outperforms a 20mg vial that yields 35 imprecise doses. Precision, not volume, determines whether your protocol replicates published mitochondrial protection data or produces equivocal results that waste months of effort and significant compound cost.

FAQs

[
{
"question": "How many doses can I get from a 10mg SS-31 vial?",
"answer": "A 10mg vial yields 10 to 40 doses depending on your target dose per injection. At 0.5mg per dose, you get 20 total doses. At 1mg per dose, you get 10 doses. At 0.25mg per dose, you get 40 doses. The total dose count is determined by dividing total vial milligrams by individual dose size, independent of reconstitution volume."
},
{
"question": "What happens if I reconstitute SS-31 with the wrong volume of water?",
"answer": "Reconstituting with incorrect volume changes your concentration but doesn't ruin the peptide. You'll just need to recalculate injection volumes. If you added 3mL instead of 2mL to a 10mg vial, your concentration is 3.33mg/mL instead of 5mg/mL. A 0.5mg dose would then require 0.15mL instead of 0.1mL. The error becomes unrecoverable only if you don't know how much water you added or which vial size you used."
},
{
"question": "Can I use regular sterile water instead of bacteriostatic water for SS-31?",
"answer": "No. Multi-dose vials require bacteriostatic water (0.9% benzyl alcohol) to prevent bacterial contamination across repeated needle punctures. Plain sterile water lacks antimicrobial preservative, meaning contamination risk increases every time you draw a dose. Single-dose protocols can use sterile water if the entire vial is used immediately after reconstitution, but standard SS-31 protocols span weeks and require bacteriostatic formulation."
},
{
"question": "How long does reconstituted SS-31 remain stable in the refrigerator?",
"answer": "Reconstituted SS-31 in bacteriostatic water remains stable for 28 days when stored at 2–8°C. Beyond this window, oxidative degradation of the dimethyltyrosine residues reduces mitochondrial-targeting efficacy unpredictably. Temperature excursions above 8°C. Even briefly. Accelerate breakdown. Lyophilized SS-31 powder stored at −20°C before reconstitution remains stable for 12 to 24 months depending on batch specifications."
},
{
"question": "What concentration should I use for subcutaneous SS-31 injections?",
"answer": "The standard research concentration is 5mg/mL, achieved by reconstituting a 10mg vial with 2mL bacteriostatic water. This concentration allows precise measurement using insulin syringes while minimizing injection volume per dose. Concentrations above 10mg/mL can cause tissue irritation; concentrations below 2mg/mL require larger injection volumes that increase measurement error and subcutaneous depot size without improving bioavailability."
},
{
"question": "Does SS-31 vial size affect peptide quality or potency?",
"answer": "No. Vial size (5mg, 10mg, 20mg) affects only total available peptide and cost per dose, not peptide quality. All vials contain the same lyophilized SS-31 tetrapeptide with identical amino-acid sequencing. Larger vials reduce per-milligram cost but require longer storage periods after reconstitution, increasing the risk of degradation if refrigeration discipline lapses. Smaller vials minimize waste if protocols change mid-study but increase per-dose cost."
},
{
"question": "Can I freeze reconstituted SS-31 to extend its shelf life?",
"answer": "Freezing reconstituted peptides is not recommended. The freeze-thaw cycle can denature protein structure and reduce potency unpredictably. If you need extended storage, keep the peptide in lyophilized form at −20°C and reconstitute only the amount you'll use within 28 days. Aliquoting reconstituted SS-31 into single-use vials and freezing them introduces contamination risk and doesn't reliably preserve activity beyond the 28-day refrigerated window."
},
{
"question": "What syringe size is best for measuring SS-31 doses accurately?",
"answer": "Insulin syringes (0.3mL to 1mL capacity with 0.01mL increment markings) provide the best measurement precision for SS-31 dosing. For doses requiring less than 0.1mL injection volume, use 0.3mL insulin syringes with finer graduations. Standard 3mL syringes lack the precision needed for doses below 0.2mL. Never reuse syringes. Worn plungers introduce measurement variability that compounds across multi-week protocols."
},
{
"question": "How do I calculate the number of doses from an SS-31 vial with a custom dose size?",
"answer": "Divide total vial milligrams by your target dose in milligrams. For example, a 20mg vial dosed at 0.75mg per injection yields 20mg ÷ 0.75mg = 26.67 doses, which rounds to 26 full doses with a small amount of peptide remaining. Then calculate concentration by dividing total milligrams by reconstitution volume, and determine injection volume by dividing dose size by concentration. Always document these calculations before starting a protocol."
},
{
"question": "Why does SS-31 require refrigeration after reconstitution but not before?",
"answer": "Lyophilized SS-31 powder is stable at room temperature for short periods because water absence prevents hydrolytic and oxidative degradation reactions. Once reconstituted, the peptide is in aqueous solution where oxidation of the dimethyltyrosine residues occurs at measurable rates even under refrigeration. The 2–8°C storage requirement slows this degradation to maintain potency for 28 days. Freezing the lyophilized powder (−20°C) further extends stability to 12–24 months."
}
]

If you're planning an SS-31 protocol and want certainty that your peptide concentration matches your dosing math, start with known variables. Real Peptides supplies research-grade SS-31 with batch-verified peptide content and exact amino-acid sequencing, eliminating vial mislabeling as a confounding factor. The number of doses you extract from each vial depends on your protocol design. But the peptide quality shouldn't be a variable you need to account for.